Anti-KRT13 antibody (400-458 aa) [ABT-CK13] (STJ196819)

SKU:
STJ196819

Current Stock:
Host: Mouse
Applications: IHC/WB
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Mouse monoclonal antibody anti-Keratin, type I cytoskeletal 13 (400-458 aa) is suitable for use in Immunohistochemistry and Western Blot research applications.
Clonality: Monoclonal
Clone ID: ABT-CK13
Conjugation: Unconjugated
Isotype: IgG1k
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen.
Dilution Range: IHC-P 1:100-500
WB 1:500-2000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: KRT13
Gene ID: 3860
Uniprot ID: K1C13_HUMAN
Immunogen Region: 400-458 aa
Specificity: This antibody detects endogenous levels of human Cytokeratin 13. Heat-induced epitope retrieval (HIER) Citrate buffer of pH6.0 was highly recommended as antigen repair method in paraffin section
Immunogen: Synthesized peptide derived from the human Cytokeratin 13 at the amino acid range 400-458
Post Translational Modifications O-glycosylated.glycans consist of single N-acetylglucosamine residues.
Function Type 1 keratin (Probable). Maintains postnatal tongue mucosal cell homeostasis and tissue organization in response to mechanical stress, potentially via regulation of the G1/S phase cyclins CCNE1 and CCNE2.
Protein Name Keratin - Type I Cytoskeletal 13
Cytokeratin-13
Ck-13
Keratin-13
K13
Database Links Reactome: R-HSA-6805567
Reactome: R-HSA-6809371
Alternative Antibody Names Anti-Keratin - Type I Cytoskeletal 13 antibody
Anti-Cytokeratin-13 antibody
Anti-Ck-13 antibody
Anti-Keratin-13 antibody
Anti-K13 antibody
Anti-KRT13 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance